Table 2.
Characteristics |
Selected NR |
Non-selected NR |
All non-selected (non-selected NR + all remitters) |
|||||
---|---|---|---|---|---|---|---|---|
(n = 57) | (n = 46) | (n = 102) | ||||||
n in Rx arm (E/S/V) | 23/14/20 | 16/18/12 | NS | 34/38/30 | NS | |||
N | % | N | % | N | % | |||
Females | 27 | 47 · 4 | 25 | 54 · 3 | NS | 52 | 51 · 0 | NS |
Melancholic⁎ | 6 | 10 · 5 | 12 | 26 · 1 | 0 · 039 | 23 | 22 · 5 | NS |
Previous treatment | 17 | 30 · 4 | 17 | 40 · 0 | NS | 53 | 52 · 0 | 0 · 009 |
Mean | SD | Mean | SD | Mean | SD | |||
Age | 37 · 7 | 12 · 2 | 35 · 1 | 13 · 2 | NS | 32 · 1 | 11 · 3 | 0 · 004 |
Rx dose (mg/day) | 63 · 2 | 51 · 5 | 54 · 6 | 41 · 7 | NS | 52 · 5 | 38 · 6 | NS |
HRSD17 Baseline | 21 · 4 | 3 · 6 | 22 · 5 | 3 · 5 | NS | 21 · 9 | 3 · 6 | NS |
HRSD17 Week 8 | 12 · 8 | 3 · 8 | 13 · 4 | 3 · 6 | NS | 8 · 7 | 5 · 1 | 0 · 000 |
HRSD17% change | 39 · 6 | 16 · 8 | 38 · 8 | 19 · 5 | NS | 59 · 8 | 23 · 9 | 0 · 000 |
Age of onset | 23 · 3 | 11 · 4 | 21 · 8 | 9 · 4 | NS | 20 · 6 | 8 · 8 | NS |
Disease duration | 14 · 0 | 10 · 0 | 12 · 8 | 14 · 2 | NS | 11 · 0 | 11 · 6 | NS |
HRSD17 anxiety | 7 · 0 | 2 · 1 | 7 · 5 | 1 · 9 | NS | 7 · 1 | 1 · 8 | NS |
HRSD17 non-anxiety | 14 · 4 | 2 · 6 | 15 · 0 | 2 · 5 | NS | 14 · 8 | 2 · 7 | NS |
FIBSER frequency | 1.74 | 1 · 32 | 1 · 46 | 1 · 39 | NS | 1 · 05 | 1 · 32 | 0 · 002 |
FIBSER intensity | 1 · 65 | 1 · 17 | 1 · 54 | 1 · 26 | NS | 1 · 12 | 1 · 20 | 0 · 008 |
FIBSER burden | 1 · 04 | 1 · 05 | 1 · 02 | 1 · 20 | NS | 0 · 73 | 1 · 03 | NS |
Abbreviations: E, escitalopram; FIBSER; Frequency, Intensity and Burden of Side Effects Rating; HRSD17, 17-item Hamilton Rating Scale for Depression; NR, Non-remitters; NS, Not significant; Rx, Medication; SD, Standard deviation; S, sertraline; V, venlafaxine-extended release.
Melancholia was defined based on a score > 7 on the Clinical Outcome in Routine Evaluation scale (Korgaonkar et al., 2011).